Iselin, New Jersey, March 23, 2026 - Today, Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company specializing in advancing the standard of care for bevacizumab in treating retina diseases, has started a best-efforts public offering of its common stock (or pre-funded warrants) along with warrants exercisable for common stock shares. The offering's completion is dependent on market conditions and other factors, with no guarantee on timing, size, or terms of the offering.